|Specificity:||The antibody 4H11[APG] reacts with Class III epitope on CD34 (Mucosialin), a 110-115 kDa monomeric transmembrane phosphoglycoprotein expressed on hematopoietic progenitors cells and on the most pluripotential stem cells; it is gradually lost on progenitor cells. The antibody 4H11[APG] completely blocks binding of Class II antibody QBEnd10 and Class III antibodies BIRMA K3 and 8G12 on KG1a cell line.
HLDA VI; WS Code M MA58
|Immunogen:||Permanent human cell line derived from peripheral leucocytes of a patient suffering from chronic myeloid leukaemia.|
Recommended dilution: 2 μg/ml
Recommended dilution: 2 μg/ml
Positive control: Kg-1a human leukemia cell lysate
Negative control: JURKAT human leukemia T-cell line
Sample preparation: Resuspend approx. 50 mil. cells in 1 ml cold Lysis buffer (1% laurylmaltoside in 20 mM Tris/Cl, 100 mM NaCl pH 8.2, 50 mM NaF including Protease inhibitor Cocktail). Incubate 60 min on ice. Centrifuge to remove cell debris. Mix lysate with non-reducing SDS-PAGE sample buffer.
Application note: Non-reducing conditions.
Immunohistochemistry (paraffin sections)
Recommended dilution: 10 μg/ml
Positive tissue: placenta endothelium
|Purity:||> 95% (by SDS-PAGE)|
|Purification:||Purified by precipitation and chromatography|
|Storage Buffer:||Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4|
|Storage / Stability:||Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.|
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD34 is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions.|
*Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G: Receptor-mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti-HPCA-1. J Hematother Stem Cell Res. 2001 Dec;10(6):863-71.
*Dao MA, Arevalo J, Nolta JA: Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood. 2003 Jan 1;101(1):112-8.
*Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Gulati S, Luthra PM: Three-dimensional structure prediction of the interaction of CD34 with the SH3 domain of Crk-L. Stem Cells Dev. 2005 Oct;14(5):470-7.
*Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM: Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem Cells Dev. 2006 Jun;15(3):305-13.
*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
*Elknerová K, Lacinová Z, Soucek J, Marinov I, Stöckbauer P: Growth inhibitory effect of the antibody to hematopoietic stem cell antigen CD34 in leukemic cell lines. Neoplasma. 2007;54(4):311-20.
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic